This company listing is no longer active
P0X Stock Overview
Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Pharnext SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.00 |
| 52 Week High | €80,000.00 |
| 52 Week Low | €0.35 |
| Beta | 313.03 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| P0X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | n/a | -4.3% | -2.5% |
| 1Y | -100.0% | -19.4% | -0.4% |
Return vs Industry: P0X underperformed the German Biotechs industry which returned -6.2% over the past year.
Return vs Market: P0X underperformed the German Market which returned 12.1% over the past year.
Price Volatility
| P0X volatility | |
|---|---|
| P0X Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: P0X has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine P0X's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 23 | Hugo Brugiere | pharnext.com |
Pharnext SA, a clinical-stage biopharmaceutical company, engages in the development of therapies for neurodegenerative diseases with high unmet medical needs. Its products include PXT3003, a novel fixed-dose synergistic combination of baclofen, naltrexone, and sorbitol formulated that is in Phase III clinical trials for the treatment of Charcot-Marie-tooth disease type 1A; and PXT864 to treat amyotrophic lateral sclerosis. The company was incorporated in 2007 and is headquartered in Paris, France.
Pharnext SA Fundamentals Summary
| P0X fundamental statistics | |
|---|---|
| Market cap | €196.46k |
| Earnings (TTM) | -€38.45m |
| Revenue (TTM) | €2.26m |
0.1x
P/S Ratio0.0x
P/E RatioIs P0X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P0X income statement (TTM) | |
|---|---|
| Revenue | €2.26m |
| Cost of Revenue | €0 |
| Gross Profit | €2.26m |
| Other Expenses | €40.70m |
| Earnings | -€38.45m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -371.82 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,702.72% |
| Debt/Equity Ratio | -66.3% |
How did P0X perform over the long term?
See historical performance and comparison